Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!' - 2The most effective method to Boost Eco-friendliness in Your Volvo XC40
- 3At UN climate conference, some activists and scientists want more talk on reforming agriculture
- 4Artemis II live updates: NASA's historic moon mission set to make lunar flyby today
- 5RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- Vote in favor of Your Number one kind of pie
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- 2026 Golden Globes: How to watch, start time, TV channel, full nominee list and more
- Satellites capture aftermath of Ethiopian volcano's 1st eruption in recorded history (images)
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- Top Pastry: What's Your Sweet Treat of Decision?
- Intriguing Strange Cruising Objections you Should Visit
